{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-026143","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.612871+00:00","generated_at":"2026-05-17T09:07:40.118386+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Enveric Biosciences moves HQ to Cambridge, MA; advances EB-003 toward IND in 2026","bullets":["Effective Sept 2, 2025, principal executive offices changed to 245 First Street, 18th Floor, Cambridge, MA 02142.","Relocation aims to leverage Boston biotech hub for talent, collaboration, and capital access.","Lead candidate EB-003 (dual 5-HT2A/5-HT1B agonist) progressing toward IND; first-in-human trial anticipated in 2026.","EB-003 designed to provide neuroplastogenic benefits without hallucinatory effects."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-026143","json":"https://secwatch.observer/filing/0001641172-25-026143.json","markdown":"https://secwatch.observer/filing/0001641172-25-026143.md","text":"https://secwatch.observer/filing/0001641172-25-026143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000164117225026143/0001641172-25-026143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000164117225026143/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:07:40.118386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}